Dieter Häussinger
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
Kalkavan H, Rathbun J, Cannon P, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang P, Drexler I, von Laer D, Wollmann G, Sharma P, Kasper S, Helfrich I, Pandyra A, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle P, Lang K. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun 2017; 8:14447.
Mar 1, 2017Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
Mar 1, 2017Nat Commun 2017; 8:14447
Kalkavan Halime, Rathbun Jessica, Cannon Paula M, Scheu Stefanie, Bauer Jens, Chauhan Jagat, Häussinger Dieter, Willimsky Gerald, Löhning Max, Schadendorf Dirk, Brandau Sven, Schuler Martin, Lang Philipp A, Drexler Ingo, von Laer Dorothee, Wollmann Guido, Sharma Piyush, Kasper Stefan, Helfrich Iris, Pandyra Aleksandra A, Gassa Asmae, Virchow Isabel, Flatz Lukas, Brandenburg Tim, Namineni Sukumar, Heikenwalder Mathias, Höchst Bastian, Knolle Percy A, Lang Karl S
Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice
Lang P, Zinkernagel R, Ohashi P, Häussinger D, Harris N, Hengartner H, Ludewig B, Kalinke U, Van Rooijen N, Cervantes-Barragan L, Kulawik A, Meryk A, Krings C, Gailus N, Borkens S, Scheu S, Honke N, Recher M, Lang K. Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice. Hepatology 2010; 52:25-32.
Mar 1, 2010Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice
Mar 1, 2010Hepatology 2010; 52:25-32
Lang Philipp A, Zinkernagel Rolf M, Ohashi Pamela S, Häussinger Dieter, Harris Nicola, Hengartner Hans, Ludewig Burkhard, Kalinke Ulrich, Van Rooijen Nico, Cervantes-Barragan Luisa, Kulawik Andreas, Meryk Andreas, Krings Caroline, Gailus Nicole, Borkens Stephanie, Scheu Stefanie, Honke Nadine, Recher Mike, Lang Karl S
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
von Wagner M, Herrmann E, Häussinger D, Bernsmeier C, Bergk A, Heintges T, Rasenack J, Hinrichsen H, Berg T, Huber M, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-7.
Aug 1, 2005Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
Aug 1, 2005Gastroenterology 2005; 129:522-7
von Wagner Michael, Herrmann Eva, Häussinger Dieter, Bernsmeier Christine, Bergk Alexandra, Heintges Tobias, Rasenack Jens, Hinrichsen Holger, Berg Thomas, Huber Miriam, Zeuzem Stefan